AUTHORS
Jorge J Castillo, MD, Shayna Sarosiek, MD2, Gottfried von Keudell, MD3, Camille Edwards, MD4, Tarek Mouhieddine, MD5, Hannah Chory, NP6, Margaret Kobs, NP7, Nina Budano8, Julia Nguyen9, Alexandra Eurell10, Courtney Boyajian11, Kirsten Meid, MPH12, Steven Treon, MD, PhD13
AFFILIATIONS
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
10 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Introduction: Pirtobrutinib and venetoclax are effective treatment for relapsed or refractory Waldenström macroglobulinemia (WM). However, when used as monotherapy, these are of indefinite duration and do not induce complete responses, with median progression-free survival (PFS) measured in a few years. Preclinical studies have shown synergistic killing effect of the combination on WM cells. We designed a study combining both agents in a fixed duration regimen with the aim of inducing deeper and more durable responses.
Methods: This is an investigator-initiated, multicenter, prospective phase II study in symptomatic, previously treated WM patients (NCT05734495). Study therapy was given in 4-week cycles. Intended therapy consisted of pirtobrutinib at 200 mg/day in cycle 1. Venetoclax was added in cycle 2 at 100 mg/day in week 1, 200 mg/day in week 2, and 400 mg/day in weeks 3 and 4, followed by pirtobrutinib 200 mg/day and venetoclax 400 mg/day given together in cycles 3-24. The outcome of interest was attaining a very good partial response (VGPR) or better. Responses were assessed using IWWM11 criteria. Assumptions included H0 15%, H1 35%, 2-sided alpha 0.03, and 0.85 power for a sample size of 44 patients. The null hypothesis will be rejected if 12 or more patients attain a VGPR or better.
Results: Between April 2023 and March 2026, 44 patients were enrolled, including 44 MYD88-mutated (MYD88MUT) and two MYD88-wild-type (MYD88WT) patients. The date cutoff for this analysis was April 30, 2026.
The baseline characteristics of the patients with MYD88MUT disease were: median age 69 years (range 41-80), 64% male sex, median of 1 prior line of therapy (range 1-4), 55% BTK inhibitor exposed, median serum IgM 2338 mg/dl (range 551-6307), median hemoglobin 10.1 g/dl (range 6.6-14.3), lymphadenopathy ≥1.5 cm 45%, splenomegaly ≥15 cm 11%, median bone marrow involvement 60% (range 5-95), CXCR4MUT 36%, TP53MUT 18%, and BTKMUT 11%.
After a median follow-up time of 17 months, CR was attained in 6 patients (14%), VGPR in 16 (36%), partial response (PR) in 19 (43%), and minor response (MR) in 2 (5%), for an overall response rate of 98%, and a VGPR/CR rate of 50%.The VGPR/CR rate was higher in patients with lymphadenopathy (68% vs. 23%; p=0.004). The median time to MR was 0.9 months, the median time to PR was 1.9 months, and the median time to VGPR/CR was 11.7 months. The 12-month VGPR/CR rate was higher in patients with lymphadenopathy (82% vs. 29%; p=0.001) and lower in patients with CXCR4MUT disease (26% vs. 75%; p=0.02). Sixteen patients are off study therapy: ten completed the 24 cycles and six stopped therapy earlier than planned (1 pancreatic cancer, 1 melanoma, 1 psychotic episode, and 1 gastrointestinal bleeding, all unrelated to study therapy, 1 diarrhea possibly related to study therapy, and 1 disease progression on study therapy). Seven patients (16%) have experienced disease progression, of whom three had completed 24 cycles of therapy, and six have started a new therapy. The estimated median time from end of therapy to disease progression was 18 months. The 18-month PFS rate is 97%. PFS appears superior in male patients (HR 0.09; 95% CI 0.01-0.84; p=0.04) and inferior in patients whose disease was refractory to covalent BTK inhibitors (HR 10.2; 95% CI 1.05-99.2; p=0.045). There were two deaths; 1 DLBCL nine months after completing study therapy, and 1 pancreatic cancer. The 18-month OS rate is 100%.
Two patients with MYD88WT disease attained MR and PR and progressed at 2 and 5 months, respectively. These findings prompted an amendment for the inclusion of only MYD88MUT patients. One of these patients died of COVID-19 after progressing on study therapy and having received a subsequent treatment; the death was considered unrelated to study therapy.
The most common treatment-related Grade ≥3 adverse events were neutropenia (34%; Grade 4: 5%), anemia (14%), thrombocytopenia (7%; Grade 4: 5%), respiratory infections (5%), diarrhea (5%), AST increase (5%) and headache, myalgia, and fatigue (2% each). All neutropenia events were reversible, and there were no events of febrile neutropenia. There have been no arrhythmia or tumor lysis events thus far.
Conclusions: The fixed-duration combination of pirtobrutinib and venetoclax induced a high VGPR/CR rate of 50% in patients with previously treated MYD88MUT WM, meeting its endpoint, without unexpected toxicities. Longer follow-up is needed to assess the response durability of the regimen.
DISCLOSURES
Jorge J Castillo, MD: Cellectar Biosciences - Research Funding; Loxo - Research Funding; Pharmacyclics - Research Funding; AbbVie - Research Funding; BeOne - Research Funding; Pharmacyclics - Consultancy (Includes expert testimony); Schrodinger - Consultancy (Includes expert testimony); BeOne - Consultancy (Includes expert testimony); Cellectar Biosciences - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Nurix - Consultancy (Includes expert testimony); Loxo - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony)